COMMUNIQUÉS West-GlobeNewswire

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
17/04/2026
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/04/2026
CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
17/04/2026
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company [...]
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
17/04/2026
Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor [...]
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
17/04/2026
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator [...]
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
17/04/2026
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
17/04/2026
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/04/2026
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
17/04/2026
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN DIEGO, April 17, 2026 [...]
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
17/04/2026
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in a syngeneic [...]
4DMT Announces New Employment Inducement Grants
17/04/2026
EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
17/04/2026
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple [...]
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
17/04/2026
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with [...]
Opticore Eye Group Unveils New Contact Lens Program in Riverside, CA for 2026
17/04/2026
Announces new contact lens program. Riverside, California, United States, April 17, 2026 (GLOBE NEWSWIRE) -- Opticore Eye Group, a leader in comprehensive eye care, is thrilled to announce the launch of its innovative [...]
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
17/04/2026
Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across [...]
JellyLean Claims Evaluated: Discover the Untold Truth About Jelly Lean Gelatin Trick Gummies Recipe for Weight Loss
17/04/2026
A 2026 informational overview addresses growing consumer interest in JellyLean gummies, the gelatin trick weight loss recipe trend, ingredient research context, pricing, and what adults searching for jelly lean [...]
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
17/04/2026
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of patients Induction [...]
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
17/04/2026
– BD200 demonstrate d superior uptake and cellular cytotoxicity when compared to approved drugs targeting either Trop - 2 or Nectin- 4 – – BD200 show ed strong anti-tumor activity across clinically relevant human tumor [...]
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
17/04/2026
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy [...]

Pages